Introduction: Metastatic renal cell carcinoma (mRCC) in recent years has been one of the diseases in the oncology that has experienced the greatest development of targeted therapies.Area covered: On one hand, more and more refined acquisitions of molecular biology are allowing a better sub-classification of this tumor, identifying new and peculiar biological profiles of patients with metastatic renal cancer that will soon be destined for increasingly tailored treatments. On the other hand, immunotherapy has, in a short time, redesigned the perimeter of our knowledge, entering clinical practice in an overpowering and convincing way. Monoclonal antibodies targeting immune checkpoint inhibitors have now entered clinical trials and have demonstrated promising antitumor effect for refractory metastatic renal cancerExpert opinion: This review summarizes the results of published and reported studies of immune checkpoint inhibitors targeted therapies enrolling patient with metastatic renal cancer.
Expert opinion on emerging drugs. 2019 Nov 21 [Epub ahead of print]
Andrea Muto, Cesare Gridelli
Division of Medical Oncology, "S. G. Moscati" Hospital, Avellino, Italy.